Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs

類似資料

• Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4)
  著者:: Home, Philip D., 等
  出版事項: (2017)
• Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial
  著者:: Bolli, Geremia B., 等
  出版事項: (2021)
• Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
  著者:: Steinstraesser, A, 等
  出版事項: (2014)
• Lower risk of severe hypoglycaemia with insulin glargine 300 U/mL versus glargine 100 U/mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials
  著者:: Danne, Thomas, 等
  出版事項: (2020)
• Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: A 12‐month comparison by concomitant sulphonylurea and/or glinide use
  著者:: Terauchi, Yasuo, 等
  出版事項: (2018)